NephroPlus: Dialysis Giant Scales New Heights with Robust Q3 and 9M FY26 Performance

Nephrocare Health Services Limited, operating under the brand NephroPlus, Asia's largest dialysis network, has reported a stellar financial performance for the third quarter and nine months ended December 31, 2025. The company's consolidated financial results reveal significant growth across key metrics, underscoring its strategic execution and expanding footprint in both domestic and international markets. This period marks a clear inflection point, with the company demonstrating strong operating leverage and disciplined capital allocation.

For Q3 FY26, NephroPlus recorded a revenue of ₹259.7 crore, marking a substantial 31.7% year-on-year growth. The nine-month period (9M FY26) saw revenue climb to ₹733.2 crore, an impressive 36.6% increase compared to the previous year. This revenue surge was primarily fueled by a 17.7% increase in treatment volumes and a favorable mix shift towards higher-priced international markets. Adjusted EBITDA for Q3 FY26 stood at ₹63.1 crore, growing by 43.0% YoY, with the margin expanding to 24.3%. For 9M FY26, Adjusted EBITDA reached ₹175.4 crore, a 52.1% increase, and the margin improved to 23.9%. The bottom line also saw remarkable improvement, with Adjusted Profit After Tax (PAT) for Q3 FY26 at ₹34.4 crore, up 71.3% YoY, and for 9M FY26, it more than doubled to ₹85.9 crore, a 103.3% increase. The annualized Return on Capital Employed (ROCE) pre-tax further strengthened to 24.7% for FY26, up from 18.7% in FY25, reflecting enhanced capital efficiency.

Operational Excellence and Strategic Expansion Drive Growth

NephroPlus's success is deeply rooted in its operational excellence and strategic expansion. The company's unique asset-light, capital-efficient operating model, combined with standardized clinical protocols and advanced technology, ensures consistent patient outcomes and healthy financial returns. This model has allowed them to scale rapidly across India and internationally, addressing the significant unmet demand for quality dialysis care.

The company's growth strategy is multi-pronged, focusing on consolidating its leadership in India, scaling operations in existing international markets like the Philippines, Uzbekistan, and Saudi Arabia, and exploring new geographies. In India, NephroPlus is expanding into micro-markets through an asset-light model, focusing on Public-Private Partnership (PPP) opportunities and developing clinic-level partnerships. This approach has proven effective, with the company pivoting from standalone clinics to a captive or shop-in-shop model within hospitals in 2011, a strategic course correction based on market realities.

Internationally, the company has successfully replicated its India-built platform in higher-priced markets. International revenues now contribute approximately 41% of the total revenue in 9M FY26, a significant jump from 12% in FY23. This expansion is driven by strategic acquisitions and a dedicated business development team focused on identifying new targets. The company's ability to leverage its lean cost structure and operational expertise in these markets has resulted in higher margins compared to local competitors.

Financial Summary

*Note: EBITDA and PAT are adjusted for Saudi expenses and notional impact of CCPS conversion where applicable. Guests and Treatments are at period end.

Future Outlook and Management Vision

Management remains confident in the company's growth trajectory, guiding for a revenue CAGR of 15%-20% over the next 3-4 years. This growth will be driven by the ramp-up of existing clinics, roll-ups of new clinics in existing markets, and opportunistic entry into new geographies or large acquisitions. The company's focus on ROCE as a primary filter for capital allocation ensures that all investments are accretive and aligned with long-term value creation.

Despite the strong performance, management acknowledges the inherent variability in the business, particularly concerning new capacity additions and large, unpredictable acquisitions. However, the overall strategy emphasizes sustained, disciplined growth. The company's healthy surplus cash position, with negative net debt of ₹283.6 crore, provides ample liquidity to fund future expansion initiatives.

NephroPlus is not just a dialysis provider; it's a mission-driven organization aiming to enable people on dialysis worldwide to lead long, happy, and productive lives. With its robust India platform, strategic international expansion, and unwavering commitment to clinical quality and patient-centric care, NephroPlus is well-positioned to capitalize on the significant headroom in the global dialysis market and continue its growth journey.